| Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects |
6 |
| Practical aspects of peptide receptor radionuclide therapy with somatostatin analogs in 2019 |
2 |
| Overview on whole body CZT cameras: The key points for the physicist |
1 |
| Etiological diagnosis of cognitive disorders and biomarkers. In which situations molecular imaging is indicated? |
1 |
| Imaging oligometastatic prostate cancer, the nuclear physician's standpoint |
1 |
| Radionuclide therapy targeting PSMA for the treatment of metastatic prostate cancer: Current point of view and ways of improvement |
1 |
| Equivalent dose rate from patients after whole-body FDG-PET/CT |
1 |
| The role of imaging in the preoperative management of primary hyperparathyroidism: A current up-date |
1 |
| Pediatric clinical illustrations |
1 |
| Head and neck carcinoma - Carcinoma of unknown origin - Salivary gland cancer |
1 |
| Adrenal incidentaloma |
1 |
| Myeloma |
0 |
| Lymphoma |
0 |
| Ovarian, cervical and endometrial cancer |
0 |
| Bone sarcoma |
0 |
| Melanoma |
0 |
| Apical left ventricular radiotracer uptake on attenuation correction with SPECT/TDM myocardial perfusion scintigraphy in non-ischemic patients |
0 |
| Breast cancer |
0 |
| Contribution of 18F-FDG PET/CT in preoperative evaluation of pheochromocytoma: Comparison with MIBG scintigraphy |
0 |
| Variability of hepatic SUVs and SULs in response assessment of avid FDG lymphoma during chemotherapy |
0 |
| Prostate cancer |
0 |
| Bladder cancer |
0 |
| Dispensing system for radiopharmaceuticals: Quality control in two hospitals and comparison with actual French regulation |
0 |
| Contribution of F-18-FDG PET/CT on non-operated prosthetic valve infective endocarditis follow-up |
0 |
| Fluorocholine PET/CT parameters predictive for hematological toxicity to (223)Radium therapy in castrate-resistant prostate cancer patients with bone metastases |
0 |
| Place of SPECT/CT of the axial skeleton in the diagnosis of bone metastases: Prospective study about 150 cases |
0 |
| Value of In-111-Pentetreotide scintigraphy and F- 18-FDG PET for clinical prognosis of patients with neuroendocrine neoplasms |
0 |
| Esophageal cancer |
0 |
| Evaluation of pulmonary perfusion SECT-CT in the prediction of postoperative pulmonary function |
0 |
| Pancreatic cancer |
0 |
| Lung, mediastinal and pleural cancer |
0 |
| Anal cancer |
0 |
| Colorectal cancer |
0 |
| CT good practices for hybrid nuclear medicine (SPECT/CT and PET/CT): Conclusion |
0 |
| Artifacts and Fitfalls/Tricks |
0 |
| Clinical illustrations in cardiology |
0 |
| Iodinated Contrast Agent (ICA) |
0 |
| Regulatory and practical aspects |
0 |
| Clinical illustrations in neurology |
0 |
| Clinical illustrations in endocrinology |
0 |
| Consideration of clinical context |
0 |
| Clinical illustrations in osteoarticular |
0 |
| Clinical illustrations in pneumology (pulmonary embolism) |
0 |
| Clinical illustrations in oncology |
0 |
| CT good practices for hybrid nuclear medicine (SPECT/CT and PET/CT): Introduction |
0 |
| Physical recalls and optimization tools for the image quality and the dose delivered to the patient |
0 |
| Evolutive profile of sympathic cardiac denervation in transthyretin hereditaryamyloidosis |
0 |
| SPECT/CT imaging of hip epiphysiolysis |
0 |
| Dosimetric study related to the preparation of( 68)Ga-radiopharmaceuticals |
0 |
| Interest of F-18-FDG PET/CT in neurofibromatosis type 10-year experience from the national reference centre Henri-Mondor |
0 |
